



FOR IMMEDIATE RELEASE

**FLAMMA sweeps 2018 CMO Leadership Awards for the 3<sup>rd</sup> year in a row**

Chignolo D'Isola, Bergamo, Italy – March 22, 2018 – Flamma SpA (“Flamma”), a preeminent Contract Manufacturing Organization (CMO) that develops, manufactures, and commercializes small molecule active pharmaceutical ingredients (APIs) for the pharmaceutical industry, is proud to announce that it has been once again awarded the maximum number of available CMO Leadership Awards for 2018.

Flamma was recognized as a Top Performer for the 3<sup>rd</sup> straight year in all 6 CMO Core Award Categories: **Expertise, Reliability, Capabilities, Quality, Service and Compatibility.**

Flamma was also been recognized as a Top Performer in all 7 Specialty Award Categories for the 3<sup>rd</sup> straight year. Those specialty categories are: **Accessible Senior Management, State-of-the-Art, Innovation, On-Time Delivery, Right the First Time, Strength of Science, and Reputation.**

There were 110 CMOs evaluated on 23 performance metrics by pharma industry sourcing professionals. **Of these 110 CMOs, Flamma was the ONLY small molecule CMO that was rated as a TOP PERFORMER in all core & specialty categories.**

“Flamma has been extremely grateful to be able to work with such a large number of vibrant customers. The entire Flamma team is thankful to be recognized by those who have worked with us and experienced the Flamma difference,” noted Kenneth Drew, Ph.D., Sr. Director North America Sales and Business Development. “Flamma continues to differentiate ourselves from others with our transparency and long term vision with customers. We are proud to be family owned and run since 1950. We do not have to answer to demands made from shareholders, private equity groups, or venture capital firms.”

Dr. Gian Paolo Negrisoni, President and CEO of Flamma remarked, “Flamma has continued to reinvest into ourselves. After the opening of our cGMP workshop at Flamma Honkai, we are also expanding at our Italian sites. We are focusing on containment and the improvement of occupational. We anticipate that later this year we will begin construction of our new R&D building at our headquarters in Chignolo. This will expand our R&D capabilities as well as allow for a dedicated analytical building. We also recently acquired additional land in Dalian that will allow us to build a new state of the art facility at Flamma Honkai.”



Life Science Leader started the CMO Leadership Awards seven years ago. Industry Standard Research (ISR) conducts the research for *Life Science Leader's* CMO Awards. For the 2018 CMO Awards data and noted earlier, more than 110 contract manufacturers were evaluated on 23 different performance metrics. Research participants were recruited from pharmaceutical companies of all sizes and were screened for decision-making influence and authority when it comes to working with CMOs. Respondents only evaluate companies with which they have worked on an outsourced project within the past 18 months. This level of qualification ensures that quality ratings come from actual involvement with a business and that companies identified as leaders are backed by experiential data. This validates these awards to be true and legitimate unlike others. **This is the only legitimate industry award based on real data from real decision makers.**

Flamma will proudly accepted its CMO Leadership Awards on March 21, 2018 at the reception and ceremony held at the W Hotel in New York City.



From L-R: Gian Paolo Negrisoni (President & CEO), Kenneth Drew (Sr. Director), Federal Equipment rep



Contact: Kenneth Drew, Ph.D.,

Sr. Director, North America Sales and Business Development

Tel: 1-617-515-0975

Email: [ken.drew@flammagroup.com](mailto:ken.drew@flammagroup.com)

**About Flamma:**

FLAMMA is a family owned & run, fully integrated CMO based in Bergamo (near Milan in Northern Italy) established in 1950.

FLAMMA is a company specialized in the cGMP manufacture of APIs, NCEs, RSMs, and advanced intermediates for the pharmaceutical industry. Flamma has particular expertise in high value chiral materials specifically amino acid related materials. Flamma also manufactures specialty compounds and advanced intermediates for the nutraceutical and cosmetic industries and has several generic products.

FLAMMA has three manufacturing facilities all with R&D labs. Both cGMP Italian locations (Chignolo & Isso) are regularly inspected by the FDA and AIFA. Flamma Honkai, located in Dalian, China, has a new R&D building as well as a cGMP production plant. Flamma provides security when working in China with our 100% owned, self-managed facilities that deliver results without worry. Flamma reliably supplies materials directly customers and/or delivers materials (when required) to their cGMP facilities in Italy in order to deliver the customer's compound on-time and in the desired specifications. Flamma offers cost-effective services to customers looking for a trusted partner within China.

Being a fully integrated company allows Flamma to move your compounds quickly along their journey taking into consideration all aspects necessary for the success of your project.

Flamma can be of assistance for early stage pre-clinical development of small molecules as well as for large-scale commercial manufacturing. With a total reactor capacity of 450 m<sup>3</sup> and over 450 employees, see why Flamma should be your next contract manufacturer. FLAMMA- WHERE IT MATTERS MOST.

For more information, please visit [www.flammagroup.com](http://www.flammagroup.com)

<https://www.linkedin.com/company/flamma-spa/>

<https://twitter.com/flammagroup>

<https://www.facebook.com/TheFlammaGroup/>